Mahatme Sandesh 4
4 · Sarepta Therapeutics, Inc. · Filed Dec 17, 2019
Insider Transaction Report
Form 4
Mahatme Sandesh
Senior Vice President, CFO
Transactions
- Exercise/Conversion
Common Stock
2019-12-13$13.71/sh+4,319$59,213→ 34,498 total - Exercise/Conversion
Common Stock
2019-12-13$13.71/sh+4,138$56,732→ 38,636 total - Sale
Common Stock
2019-12-13$125.50/sh−125,000$15,687,500→ 30,179 total - Exercise/Conversion
Stock option (right to buy)
2019-12-13−4,138→ 2,633 totalExercise: $13.71From: 2016-09-09Exp: 2026-02-28→ Common Stock (4,138 underlying) - Exercise/Conversion
Common Stock
2019-12-13$29.03/sh+69,479$2,016,975→ 118,581 total - Exercise/Conversion
Stock option (right to buy)
2019-12-13−69,479→ 0 totalExercise: $29.03From: 2015-02-28Exp: 2024-02-28→ Common Stock (69,479 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-12-13−14,723→ 39,277 totalExercise: $34.92From: 2014-06-04Exp: 2023-06-04→ Common Stock (14,723 underlying) - Exercise/Conversion
Common Stock
2019-12-13$23.85/sh+10,466$249,614→ 49,102 total - Exercise/Conversion
Common Stock
2019-12-13$32.63/sh+21,875$713,781→ 140,456 total - Exercise/Conversion
Common Stock
2019-12-13$34.92/sh+14,723$514,127→ 155,179 total - Exercise/Conversion
Stock option (right to buy)
2019-12-13−4,319→ 3,085 totalExercise: $13.71From: 2017-02-28Exp: 2026-02-28→ Common Stock (4,319 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-12-13−10,466→ 0 totalExercise: $23.85From: 2013-11-05Exp: 2022-11-05→ Common Stock (10,466 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-12-13−21,875→ 10,874 totalExercise: $32.63From: 2018-03-10Exp: 2027-03-10→ Common Stock (21,875 underlying)
Holdings
- 12,012(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.